The effect of finasteride in men with benign prostatic hyperplasia

Glenn J. Gormley, Elizabeth Stoner, Reginald C. Bruskewitz, Julianne Imperato-Mcginley, Patrick Walsh, John D. Mcconnell, Gerald L. Andriole, Jack Geller, Bruce R. Bracken, Joyge S. Tenover, E. Darracott Vaughan, Frances Pappas, Alice Taylor, Bruce Binkowitz, Jennifer Ng

Research output: Contribution to journalArticle

Abstract

Background. Benign prostatic hyperplasia is a progressive, androgen-dependent disease resulting in enlargement of the prostate gland and urinary obstruction. Preventing the conversion of testosterone to its tissueactive form, dihydrotestosterone, by inhibiting the enzyme 5α-reductase could decrease the action of androgens in their target tissues; in the prostate the result might be a decrease in prostatic hyperplasia and therefore in symptoms of urinary obstruction. Methods. In a double-blind study, we evaluated the effect of two doses of finasteride (1 mg and 5 mg) and placebo, each given once daily for 12 months, in 895 men with prostatic hyperplasia. Urinary symptoms, urinary flow, prostatic volume, and serum concentrations of dihydrotestosterone and prostate-specific antigen were determined periodically during the treatment period. Results. As compared with the men in the placebo group, the men treated with 5 mg of finasteride per day had a significant decrease in total urinary-symptom scores (P

Original languageEnglish (US)
Pages (from-to)1185-1191
Number of pages7
JournalNew England Journal of Medicine
Volume327
Issue number17
StatePublished - Oct 22 1992

Fingerprint

Finasteride
Prostatic Hyperplasia
Dihydrotestosterone
Androgens
Prostate
Placebos
Prostate-Specific Antigen
Double-Blind Method
Testosterone
Oxidoreductases
Enzymes
Serum
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-Mcginley, J., Walsh, P., Mcconnell, J. D., ... Ng, J. (1992). The effect of finasteride in men with benign prostatic hyperplasia. New England Journal of Medicine, 327(17), 1185-1191.

The effect of finasteride in men with benign prostatic hyperplasia. / Gormley, Glenn J.; Stoner, Elizabeth; Bruskewitz, Reginald C.; Imperato-Mcginley, Julianne; Walsh, Patrick; Mcconnell, John D.; Andriole, Gerald L.; Geller, Jack; Bracken, Bruce R.; Tenover, Joyge S.; Vaughan, E. Darracott; Pappas, Frances; Taylor, Alice; Binkowitz, Bruce; Ng, Jennifer.

In: New England Journal of Medicine, Vol. 327, No. 17, 22.10.1992, p. 1185-1191.

Research output: Contribution to journalArticle

Gormley, GJ, Stoner, E, Bruskewitz, RC, Imperato-Mcginley, J, Walsh, P, Mcconnell, JD, Andriole, GL, Geller, J, Bracken, BR, Tenover, JS, Vaughan, ED, Pappas, F, Taylor, A, Binkowitz, B & Ng, J 1992, 'The effect of finasteride in men with benign prostatic hyperplasia', New England Journal of Medicine, vol. 327, no. 17, pp. 1185-1191.
Gormley GJ, Stoner E, Bruskewitz RC, Imperato-Mcginley J, Walsh P, Mcconnell JD et al. The effect of finasteride in men with benign prostatic hyperplasia. New England Journal of Medicine. 1992 Oct 22;327(17):1185-1191.
Gormley, Glenn J. ; Stoner, Elizabeth ; Bruskewitz, Reginald C. ; Imperato-Mcginley, Julianne ; Walsh, Patrick ; Mcconnell, John D. ; Andriole, Gerald L. ; Geller, Jack ; Bracken, Bruce R. ; Tenover, Joyge S. ; Vaughan, E. Darracott ; Pappas, Frances ; Taylor, Alice ; Binkowitz, Bruce ; Ng, Jennifer. / The effect of finasteride in men with benign prostatic hyperplasia. In: New England Journal of Medicine. 1992 ; Vol. 327, No. 17. pp. 1185-1191.
@article{603559624dcc449a80b6a4b62a26c980,
title = "The effect of finasteride in men with benign prostatic hyperplasia",
abstract = "Background. Benign prostatic hyperplasia is a progressive, androgen-dependent disease resulting in enlargement of the prostate gland and urinary obstruction. Preventing the conversion of testosterone to its tissueactive form, dihydrotestosterone, by inhibiting the enzyme 5α-reductase could decrease the action of androgens in their target tissues; in the prostate the result might be a decrease in prostatic hyperplasia and therefore in symptoms of urinary obstruction. Methods. In a double-blind study, we evaluated the effect of two doses of finasteride (1 mg and 5 mg) and placebo, each given once daily for 12 months, in 895 men with prostatic hyperplasia. Urinary symptoms, urinary flow, prostatic volume, and serum concentrations of dihydrotestosterone and prostate-specific antigen were determined periodically during the treatment period. Results. As compared with the men in the placebo group, the men treated with 5 mg of finasteride per day had a significant decrease in total urinary-symptom scores (P",
author = "Gormley, {Glenn J.} and Elizabeth Stoner and Bruskewitz, {Reginald C.} and Julianne Imperato-Mcginley and Patrick Walsh and Mcconnell, {John D.} and Andriole, {Gerald L.} and Jack Geller and Bracken, {Bruce R.} and Tenover, {Joyge S.} and Vaughan, {E. Darracott} and Frances Pappas and Alice Taylor and Bruce Binkowitz and Jennifer Ng",
year = "1992",
month = "10",
day = "22",
language = "English (US)",
volume = "327",
pages = "1185--1191",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "17",

}

TY - JOUR

T1 - The effect of finasteride in men with benign prostatic hyperplasia

AU - Gormley, Glenn J.

AU - Stoner, Elizabeth

AU - Bruskewitz, Reginald C.

AU - Imperato-Mcginley, Julianne

AU - Walsh, Patrick

AU - Mcconnell, John D.

AU - Andriole, Gerald L.

AU - Geller, Jack

AU - Bracken, Bruce R.

AU - Tenover, Joyge S.

AU - Vaughan, E. Darracott

AU - Pappas, Frances

AU - Taylor, Alice

AU - Binkowitz, Bruce

AU - Ng, Jennifer

PY - 1992/10/22

Y1 - 1992/10/22

N2 - Background. Benign prostatic hyperplasia is a progressive, androgen-dependent disease resulting in enlargement of the prostate gland and urinary obstruction. Preventing the conversion of testosterone to its tissueactive form, dihydrotestosterone, by inhibiting the enzyme 5α-reductase could decrease the action of androgens in their target tissues; in the prostate the result might be a decrease in prostatic hyperplasia and therefore in symptoms of urinary obstruction. Methods. In a double-blind study, we evaluated the effect of two doses of finasteride (1 mg and 5 mg) and placebo, each given once daily for 12 months, in 895 men with prostatic hyperplasia. Urinary symptoms, urinary flow, prostatic volume, and serum concentrations of dihydrotestosterone and prostate-specific antigen were determined periodically during the treatment period. Results. As compared with the men in the placebo group, the men treated with 5 mg of finasteride per day had a significant decrease in total urinary-symptom scores (P

AB - Background. Benign prostatic hyperplasia is a progressive, androgen-dependent disease resulting in enlargement of the prostate gland and urinary obstruction. Preventing the conversion of testosterone to its tissueactive form, dihydrotestosterone, by inhibiting the enzyme 5α-reductase could decrease the action of androgens in their target tissues; in the prostate the result might be a decrease in prostatic hyperplasia and therefore in symptoms of urinary obstruction. Methods. In a double-blind study, we evaluated the effect of two doses of finasteride (1 mg and 5 mg) and placebo, each given once daily for 12 months, in 895 men with prostatic hyperplasia. Urinary symptoms, urinary flow, prostatic volume, and serum concentrations of dihydrotestosterone and prostate-specific antigen were determined periodically during the treatment period. Results. As compared with the men in the placebo group, the men treated with 5 mg of finasteride per day had a significant decrease in total urinary-symptom scores (P

UR - http://www.scopus.com/inward/record.url?scp=0026806486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026806486&partnerID=8YFLogxK

M3 - Article

C2 - 1383816

AN - SCOPUS:0026806486

VL - 327

SP - 1185

EP - 1191

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 17

ER -